Gilead Sciences’ (GILD) Outperform Rating Reaffirmed at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $105.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently commented on GILD. Wells Fargo & Company reduced their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating for the company in a research report on Monday, March 4th. UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a neutral rating on the stock in a report on Wednesday, April 17th. Truist Financial cut Gilead Sciences from a buy rating to a hold rating and cut their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $75.00 and set a sector perform rating on the stock in a report on Wednesday, February 14th. Finally, Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an equal weight rating on the stock in a report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $84.71.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $66.95 on Friday. The company has a market cap of $83.36 billion, a price-to-earnings ratio of 14.88, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. Gilead Sciences has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm has a 50 day moving average of $71.81 and a 200-day moving average of $76.51.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business earned $1.67 EPS. On average, equities analysts forecast that Gilead Sciences will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.60%. The ex-dividend date was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is presently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.29% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently bought and sold shares of the company. OFI Invest Asset Management bought a new stake in Gilead Sciences in the third quarter valued at approximately $26,000. Tompkins Financial Corp increased its stake in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares during the period. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Finally, Sachetta LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $30,000. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.